当前位置: X-MOL 学术J. Clin. Invest. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
The Journal of Clinical Investigation ( IF 13.3 ) Pub Date : 2021 , DOI: 10.1172/jci150535
Nikolaj Pagh Kristensen 1 , Christina Heeke 1 , Siri A Tvingsholm 1 , Annie Borch 1 , Arianna Draghi 2 , Michael D Crowther 2 , Ibel Carri 3 , Kamilla K Munk 1 , Jeppe Sejerø Holm 1 , Anne-Mette Bjerregaard 1 , Amalie Kai Bentzen 1 , Andrea M Marquard 1 , Zoltan Szallasi 4 , Nicholas McGranahan 5 , Rikke Andersen 2 , Morten Nielsen 3, 6 , Göran B Jönsson 7 , Marco Donia 2 , Inge Marie Svane 2 , Sine Reker Hadrup 1
Affiliation  

BACKGROUND. Neoantigen-driven recognition and T cell–mediated killing contribute to tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs). Yet how diversity, frequency, and persistence of expanded neoepitope-specific CD8+ T cells derived from TIL infusion products affect patient outcome is not fully determined.

中文翻译:

新抗原反应性 CD8+ T 细胞影响黑色素瘤中肿瘤浸润淋巴细胞过继细胞治疗的临床结果

背景。新抗原驱动的识别和 T 细胞介导的杀伤有助于肿瘤浸润淋巴细胞 (TIL) 过继细胞治疗 (ACT) 后的肿瘤清除。然而,源自 TIL 输注产品的扩增的新表位特异性 CD8 + T 细胞的多样性、频率和持久性如何影响患者的预后尚未完全确定。
更新日期:2022-01-19
down
wechat
bug